It depends on what he has to say. Previously, CC's have resulted in drop in share price. However, he if has something substantive and specific to say, it will help. Problem is that NP can't keep to timelines. There are some potentially significant updates on this list:

1) BLA submissions to Health Canada, MHRA, EMA, and US FDA *
2) HIV prevention trial/monotherapy trial *
3) Potential revenue from HIV and manufacturing forecast *
4) HIV Cure - amfAR *
5) EUA submission timelines to same four agencies for COVID-19 *
6) Long-hauler clinical trial and potential data readout timelines *
7) NASH trial and potential interim analysis timeline *
Cancer trial Breakthrough Therapy designation potential timelines *
9) GvHD trial status *
10) Stroke/MS new trials in 2021 *
11) NASDAQ uplisting status *

What investor is not interested in updates on these topics? But they have to be substantive, significant, and timely.